Key result
Gallic acid reduces doxorubicin-induced renal injury in rats by blunting oxidative stress and inflammation.
Why the study?
This study was conducted to evaluate the protective effects of Gallic acid against doxorubicin-induced renal injury and explore the underlying molecular interactions.
Does gallic acid protect against doxorubicin-induced nephrotoxicity in rats?
RCT (n=50)
randomly assigned
Does gallic acid protect against doxorubicin-induced nephrotoxicity in rats?
Gallic acid demonstrates dose-dependent renoprotective effects against doxorubicin-induced nephrotoxicity in a rat model through modulation of oxidative, inflammatory, and apoptotic pathways.
Hypothesis-generating for gallic acid renoprotection; does not support clinical use.
Objective(s): This study aimed to evaluate the protective effects of Gallic acid (GA) against (Doxorubicin) DOX-induced renal injury and to explore potential molecular interactions underlying its effects. Materials and Methods: Fifty male rats were randomly assigned to five groups: Control, DOX, GA50+DOX, GA100+DOX, and GA100. DOX was administered as a single intraperitoneal dose on day 8 (40 mg/kg), while GA was given orally at 50 or 100 mg/kg for 10 consecutive days. Renal tissues were collected on day 11 and analyzed for oxidative stress markers, pro- and anti-inflammatory cytokines, and the apoptotic marker caspase-3 via ELISA. Immunohistochemistry assessed Nrf-2 and HO-1 expression, and histopathology evaluated structural alterations. Molecular docking simulations were performed for DOX/topoisomerase IIα (PDB ID: 4FM9) and GA/TNF-α (PDB ID: 2AZ5). Results: GA significantly ameliorated DOX-induced oxidative stress, inflammatory cytokine imbalance, caspase-3 activation, and histological damage in a dose-dependent manner, while enhancing Nrf-2 and HO-1 expression. Docking analysis confirmed DOX binding to topoisomerase IIα and revealed strong GA–TNF-α binding affinity. Conclusion: GA exerts substantial renoprotective effects against DOX-induced nephrotoxicity by modulating oxidative, inflammatory, and apoptotic pathways. The agreement between in vivo findings and in silico modeling supports GA as a potential complementary agent to reduce chemotherapy-related renal injury.
No takes yet. Share an insight, caveat, or question.
Teki̇n et al. (2026) conducted an RCT in Doxorubicin-induced nephrotoxicity (n=50). Gallic acid vs. DOX alone, Control, and GA100 alone was evaluated on Renal injury assessed via oxidative stress markers, cytokines, caspase-3, Nrf-2, HO-1 expression, and histopathology. Gallic acid (50 or 100 mg/kg) significantly ameliorated doxorubicin-induced oxidative stress, inflammatory cytokine imbalance, caspase-3 activation, and histological damage in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: